Rajen J. Mody

University of Michigan
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (8)

Contains supplementary data and table titles and as well as supplementary figures with associated titles and legends.Fig. S1. Selection method for planned efficacy analysis of ONC201 in patients with H3K27MDMG.Fig. S2. Progression-free survival from diagnosis of trial patients with non-recurrent H3K27MDMG treated with ONC201.Fig. S3. Swimmers’ plot of ONC201 response by recurrence status, tumor location, and ONC201 trial.Fig. S4. ONC201 efficacy is independent of TP53 mutation status and chromosomal instability.Fig. S5. Cox proportional hazard regression to assess the effect of ONC201 after adjusting for confounders.Fig. S6. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated historical controls.Fig. S7. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated patients (PNOC003 or HERBY Phase II trials).Fig. S8. Molecular attributes of patients with H3K27M-DMG treated with ONC201.Fig. S9: Survival of H3K27M-DMG mice models treated with ONC201.Fig. S10. Integrative analysis of in vitro and human tumor metabolic gene expression in response to ONC201.Fig. S11. ONC201-mediated L2HG production increases H3K27me3 in H3K27M-DMG cells.Fig. S12. ONC201-induced increase in H3K27me3 is mediated by lactate dehydrogenase.Fig. S13. ONC201 alters genomic chromatin accessibility and H3K27ac distribution in H3K27M-DMG cells.Fig. S14. ONC201 increases global H3K27me3 in patient samples.Fig. S15. ONC201 does not cause hypermethylation leading to a glioma CpG island methylator phenotype.

Year:

2025

Patients with H3K27M-mutant diffuse midline glioma (DMG) have no proven effective therapies. ONC201 has recently demonstrated efficacy in these patients, but the mechanism behind this finding remains unknown. We assessed clinical outcomes, tumor sequencing, and tissue/cerebrospinal fluid (CSF) correlate samples from patients treated in two completed multisite clinical studies. Patients treated with ONC201 following initial radiation but prior to recurrence demonstrated a median overall survival of 21.7 months, whereas those treated after recurrence had a median overall survival of 9.3 months. Radiographic response was associated with increased expression of key tricarboxylic acid cycle–related genes in baseline tumor sequencing. ONC201 treatment increased 2-hydroxyglutarate levels in cultured H3K27M-DMG cells and patient CSF samples. This corresponded with increases in repressive H3K27me3 in vitro and in human tumors accompanied by epigenetic downregulation of cell cycle regulation and neuroglial differentiation genes. Overall, ONC201 demonstrates efficacy in H3K27M-DMG by disrupting integrated metabolic and epigenetic pathways and reversing pathognomonic H3K27me3 reduction. Significance: The clinical, radiographic, and molecular analyses included in this study demonstrate the efficacy of ONC201 in H3K27M-mutant DMG and support ONC201 as the first monotherapy to improve outcomes in H3K27M-mutant DMG beyond radiation. Mechanistically, ONC201 disrupts integrated metabolic and epigenetic pathways and reverses pathognomonic H3K27me3 reduction. This article is featured in Selected Articles from This Issue, p. 2293

Year:

2025

PURPOSE Paired tumor-germline sequencing can identify somatic variants for targeted therapy and germline pathogenic variants (GPVs) causative of hereditary cancer/tumor predisposition syndromes. It is unknown how patients/families in pediatric oncology use information about an identified GPV. We assessed recall of germline results and actions taken on the basis of findings. METHODS We completed phone surveys with patients (and/or their parent) with GPVs identified via a single academic medical center's paired tumor-germline sequencing study. Seven hundred forty pediatric (aged 0-25 years) oncology patients were enrolled in this sequencing study between May 2012 and August 2021. Ninety-six participants (13.0%) had at least one GPV identified and were therefore eligible for this survey. The parent/guardian (for patients younger than 18 years or deceased patients) or patients themselves (if 18 years or older) were contacted. Survey topics included germline result recall, experience with genetic counseling, changes to patient's cancer treatment/screening, sharing of results with family members, and lifestyle changes. RESULTS Fifty-three surveys (response rate, 55.2%) were completed between October 2021 and June 2022. Thirty-seven (69.8%) respondents correctly recalled the identified GPV. Discussing results with a genetic counselor ( P = .0001), having a GPV related to the cancer/tumor diagnosis ( P = .002), and non-Hispanic White race/ethnicity ( P = .02) were associated with accurate recall. Twenty-five respondents (47.2%) reported a change in the child's cancer treatment and/or screening recommendations, 17 respondents (32.1%) made a lifestyle change on the basis of the results, and 44 respondents (83.0%) shared results with at least one family member. CONCLUSION While most respondents remembered that a GPV was identified in the patient, some did not recall having a GPV found, and others recalled germline findings incorrectly. Future work may determine patient/family preferences for timing/method of result return to optimize patient recall and use of germline results.

Year:

2024

Contains supplementary data and table titles and as well as supplementary figures with associated titles and legends. Fig. S1. Selection method for planned efficacy analysis of ONC201 in patients with H3K27MDMG. Fig. S2. Progression-free survival from diagnosis of trial patients with non-recurrent H3K27MDMG treated with ONC201. Fig. S3. Swimmers’ plot of ONC201 response by recurrence status, tumor location, and ONC201 trial. Fig. S4. ONC201 efficacy is independent of TP53 mutation status and chromosomal instability. Fig. S5. Cox proportional hazard regression to assess the effect of ONC201 after adjusting for confounders. Fig. S6. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated historical controls. Fig. S7. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated patients (PNOC003 or HERBY Phase II trials). Fig. S8. Molecular attributes of patients with H3K27M-DMG treated with ONC201. Fig. S9: Survival of H3K27M-DMG mice models treated with ONC201. Fig. S10. Integrative analysis of in vitro and human tumor metabolic gene expression in response to ONC201. Fig. S11. ONC201-mediated L2HG production increases H3K27me3 in H3K27M-DMG cells. Fig. S12. ONC201-induced increase in H3K27me3 is mediated by lactate dehydrogenase. Fig. S13. ONC201 alters genomic chromatin accessibility and H3K27ac distribution in H3K27M-DMG cells. Fig. S14. ONC201 increases global H3K27me3 in patient samples. Fig. S15. ONC201 does not cause hypermethylation leading to a glioma CpG island methylator phenotype.

Year:

2024

Contains supplementary data and table titles and as well as supplementary figures with associated titles and legends. Fig. S1. Selection method for planned efficacy analysis of ONC201 in patients with H3K27MDMG. Fig. S2. Progression-free survival from diagnosis of trial patients with non-recurrent H3K27MDMG treated with ONC201. Fig. S3. Swimmers’ plot of ONC201 response by recurrence status, tumor location, and ONC201 trial. Fig. S4. ONC201 efficacy is independent of TP53 mutation status and chromosomal instability. Fig. S5. Cox proportional hazard regression to assess the effect of ONC201 after adjusting for confounders. Fig. S6. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated historical controls. Fig. S7. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated patients (PNOC003 or HERBY Phase II trials). Fig. S8. Molecular attributes of patients with H3K27M-DMG treated with ONC201. Fig. S9: Survival of H3K27M-DMG mice models treated with ONC201. Fig. S10. Integrative analysis of in vitro and human tumor metabolic gene expression in response to ONC201. Fig. S11. ONC201-mediated L2HG production increases H3K27me3 in H3K27M-DMG cells. Fig. S12. ONC201-induced increase in H3K27me3 is mediated by lactate dehydrogenase. Fig. S13. ONC201 alters genomic chromatin accessibility and H3K27ac distribution in H3K27M-DMG cells. Fig. S14. ONC201 increases global H3K27me3 in patient samples. Fig. S15. ONC201 does not cause hypermethylation leading to a glioma CpG island methylator phenotype.

Year:

2024

H3K27M-mutant diffuse midline glioma (DMG) patients have no proven effective therapies. ONC201 has recently demonstrated efficacy in these patients, but the mechanism behind this remains unknown. We assessed clinical outcomes, tumor sequencing, and tissue/CSF correlate samples from patients treated in two completed multi-site clinical studies. Patients treated with ONC201 following initial radiation but prior to recurrence demonstrated a median overall survival of 21.7 months, while those treated after recurrence had a median overall survival of 9.3 months. Radiographic response was associated with increased expression of key tricarboxylic acid cycle-related genes in baseline tumor sequencing. ONC201 treatment increased 2-hydroxyglutarate levels in cultured H3K27M-DMG cells and patient CSF samples. This corresponded with increases in repressive H3K27me3 in vitro and in human tumors accompanied by epigenetic downregulation of cell cycle regulation and neuro-glial differentiation genes. Overall, ONC201 demonstrates efficacy in H3K27M-DMG by disrupting integrated metabolic and epigenetic pathways and reversing pathognomonic H3K27me3 reduction.

Year:

2024

Introduction: Germ cell tumors (GCT) encompass a wide variety of neoplasms with varying clinical behavior dependent on histology, staging, and site. GCT remain relatively uncommon in the pediatric population and most patients have a favorable prognosis. However, the well-established co-occurrence of primary mediastinal GCT (PMGCT) and acute myeloid leukemia (AML) has a dismal prognosis with few reported patients achieving sustained remission. Case presentation: An 18 y.o. male was concurrently diagnosed with PMGCT and AML, type M7. Cytogenetic analysis revealed a complex set of chromosomal alterations along with homozygous deletion of TP53. His concurrent oncologic processes were managed with a variety of chemotherapy regimens, complete surgical resection of the mediastinal mass, and hematopoietic stem cell transplant (HSCT). He is one of few patients with concurrent PMGCT and AML able to achieve remission with no evidence of disease nearly 5 years after completion of treatment. Conclusion: The rare, but well-identified, association between PMGCT and concurrent or subsequent AML has a dismal prognosis. Modern genetics sequencing has identified common aberrations, including i(12p), trisomy/tetrasomy 8, TP53, and PTEN mutations. With this knowledge, it may allow for future tailoring of therapy to improve the predicted outcome of patients with PMGCT and AML.

Year:

2024

During the COVID-19 pandemic, pediatric oncology patients, caregivers, and providers were required to adapt to changes in healthcare delivery to minimize the risk of COVID-19 exposure. This study evaluated the impact of the pandemic on oncologic care and patient and caregiver distress by surveying patients actively followed for cancer treatment or on surveillance. Adherence to therapy and access to the oncology team was largely maintained with increased virtual visits. Due to concern for exposure and disruptions to work, social stressor screening and support are warranted. Continuing access to up-to-date information about COVID-19 is critical as the pandemic continues to evolve.

Year:

2024

Collaborators (29)

Matthew Hall

Associate Clinical Professor

Florida International University

UNITED STATES
View details

Chandan Kumar

Associate Research Scientist

University of Michigan

UNITED STATES
View details

Adam Resnick

Director

University of Pennsylvania

UNITED STATES
View details

Sebastian Waszak

Tenure Track Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Mariella Filbin

Dana-Farber Cancer Institute

UNITED STATES
View details

Arul M Chinnaiyan

University of Michigan

UNITED STATES
View details

Yoshie Umemura

Barrow Neurological Institute

UNITED STATES
View details

minesh mehta

Chair

Florida International University

UNITED STATES
View details

Anna Schwendeman

-

UNITED STATES
View details

Timothy Cloughesy

Director of NeuroOncology Program/Professor

Ronald Reagan UCLA Medical Center

UNITED STATES
View details

Michelle M Kim

University of Michigan

UNITED STATES
View details

Sriram Venneti

Professor

University of Michigan

UNITED STATES
View details

Lili Zhao

Professor

Northwestern University

UNITED STATES
View details

Charles Burant

University of Michigan

UNITED STATES
View details

Sabine Mueller

Adjunt Associate Professor

University of California

UNITED STATES
View details

Nathalie Agar

Principal Investigator

Brigham and Women's Hospital

UNITED STATES
View details

Rajan Jain

Professor

NYU Langone Health

UNITED STATES
View details

Matthew Dun

Professor Paediatric Heamatology/Oncology Research

Hunter Medical Research Institute

AUSTRALIA
View details

Susanne Schmidt

Group Leader

University of Bonn

GERMANY
View details

Carl Koschmann

University of Michigan Medical School

UNITED STATES
View details

Andrea T. Franson

-

UNITED STATES
View details

Javad Nazarian

Lead, DMG Research Center

-

SWITZERLAND
View details

Laura Sedig

-

UNITED STATES
View details

Chan Chung

Principal investigator

Daegu Gyeongbuk Institute of Science and Technology

SOUTH KOREA
View details

Benjamin M Ellingson

Professor

University of California, Los Angeles

UNITED STATES
View details

Daniel R. Wahl

University of Michigan

UNITED STATES
View details

Jacques Grill

Head day care

Gustave Roussy

FRANCE
View details

Costas A. Lyssiotis

University of Michigan

UNITED STATES
View details

Sharon L Gardner

Associate Professor (Clinical) of Pediatrics

NYU School of Medicine

UNITED STATES
View details